Document is current
Any future updates will be listed below
-
Authors
Finney Rutten, Lila J.
Radecki Breitkopf, Carmen
St. Sauver, Jennifer L.
Croghan, Ivana T.
Jacobson, Debra J.
Wilson, Patrick M.
Herrin, Jeph
Jacobson, Robert M.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA217889)
- License Information
-
More Information
Article History
Received: 10 May 2018
Accepted: 7 June 2018
First Online: 13 July 2018
Ethics approval and consent to participate
: The protocol described herein was approved as a minimal risk study by the Mayo Clinic IRB on February 21, 2018, as IRB No. 17-010661. Persons who participate in the planned focus groups will be asked to provide written consent.
: Not applicable.
: LJFR, ITC, CRB, JH, PMW, DJJ, and JLSS have no competing interests to declare. RMJ serves as a member of a safety review committee for a postlicensure safety study of Gardasil (4vHPV) and one for a postlicensure safety study of Gardasil 9 (9vHPV). He also serves on a data-monitoring committee for a series of prelicensure trials of a 15-valent pneumococcal vaccine. All of these studies are funded by Merck & Co, Inc.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
